CC
IBRX icon

Courier Capital’s ImmunityBio IBRX Stock Holding History

Courier Capital’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$490K Hold
56,000
– – 0.02% 290
2026
Q1 		$430K Hold
56,000
– – 0.02% 292
2025
Q4 		$111K Buy
56,000
+6,000
+12% +$13.6K 0.01% 381
2025
Q3 		$123K Buy
50,000
+5,000
+11% +$12.9K 0.01% 387
2025
Q2 		$119K Buy
45,000
+5,000
+13% +$13.4K 0.01% 382
2025
Q1 		$120K Buy
40,000
+10,000
+33% +$30.3K 0.01% 370
2024
Q4 		$76.8K Hold
30,000
– – 0.01% 359
2024
Q3 		$112K Buy
30,000
+10,000
+50% +$46.3K 0.01% 356
2024
Q2 		$126K Hold
20,000
– – 0.01% 337
2024
Q1 		$107K Buy
20,000
+5,000
+33% +$22.6K 0.01% 356
2023
Q4 		$75.3K Buy
+15,000
New +$47.1K 0.01% 354

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Courier Capital's IBRX Position: Q2 2026 in Review

Courier Capital held its ImmunityBio (IBRX) position steady in Q2 2026 at 56,000 shares worth $490K. The position accounts for 0.02% of the portfolio, ranked #290.

Courier Capital first reported a position in IBRX in Q4 2023 and has held it in 11 quarters since. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Courier Capital held 56,000 shares of ImmunityBio worth $490K as of Q2 2026.
  • Courier Capital left its ImmunityBio share count unchanged in Q2 2026.
  • ImmunityBio made up 0.02% of Courier Capital's portfolio in Q2 2026, its #290 holding.
  • Courier Capital first reported a position in ImmunityBio in Q4 2023 and has held it in 11 quarters since.
  • 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Courier Capital's 13F filing for Q2 2026, filed 16 Jul 2026.